Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Results From the REsCue Trial: A Randomized Controlled Trial with Extended-Release Calcifediol in Symptomatic Outpatients with COVID-19

Charles W. Bishop, Akhtar Ashfaq, Joel Z. Melnick, Enrique Vazquez-Escarpanter, Jonathan A. Fialkow, Stephen A. Strugnell, John Choe, Kamyar Kalantar-Zadeh, Noah C. Federman, David Ng, John S. Adams
doi: https://doi.org/10.1101/2022.01.31.22270036
Charles W. Bishop
aRenal Division, OPKO Health, Miami, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akhtar Ashfaq
aRenal Division, OPKO Health, Miami, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joel Z. Melnick
bSCDadvisor, Evanston, IL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Enrique Vazquez-Escarpanter
cKendall South Medical Center, Miami, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan A. Fialkow
dCardiovascular Research Center of South Florida, Miami, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen A. Strugnell
aRenal Division, OPKO Health, Miami, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sstrugnell@opko.com
John Choe
aRenal Division, OPKO Health, Miami, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kamyar Kalantar-Zadeh
eDivision of Nephrology, Hypertension and Kidney Transplantation, University of California Irvine, Orange, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noah C. Federman
fDepartment of Pediatrics, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Ng
gWuXi Clinical Development, Austin, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John S. Adams
gWuXi Clinical Development, Austin, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Importance The benefit of vitamin D treatment for coronavirus disease 2019 (COVID-19) remains unclear.

Objective To investigate the effect of raising serum total 25-hydroxyvitamin D (25D) to 50-100 ng/mL with oral extended-release calcifediol (ERC) on time to symptom resolution in mild to moderate COVID-19.

Design, Setting, and Participants A multicenter, randomized, double-blind, placebo-controlled study evaluated treatment of 160 outpatients with COVID-19 diagnosed between November 2020 and October 2021.

Interventions Patients were treated for 4 weeks with ERC (30 mcg/capsule; 300 mcg on Days 1-3 and 60 mcg on Days 4-27) or placebo.

Outcome Measures Primary endpoints were raising serum 25D to ≥50 ng/mL at Day 14 and resolution time for five aggregated symptoms. Secondary endpoints included resolution time for aggregated and individual symptoms as a function of serum 25D and changes in clinical biomarkers.

Results 171 subjects randomized, 160 treated and 134 (65 ERC and 69 placebo) retained. Average age was 43 (range: 18-71); 59% female, 92% White, 80% Hispanic, 7% African-American, 1% Other, 76% overweight, 40% obese, 26% comorbidities, mean baseline 25D of 37±1 (SE) ng/mL. ERC increased mean 25D to 82±4 ng/mL (p<0.001) by Day 7; 88% of subjects attained a level ≥50 ng/mL; the placebo group trended lower. Resolution time for five aggregated symptoms was unchanged by ERC given that two composite non-respiratory symptoms responded poorly. Prespecified analyses showed that respiratory symptoms tended to resolve earlier when serum 25D levels reached ≤50 ng/mL, but statistical significance was limited by small sample size and non-compliance: 25D increased in seven placebo subjects (unauthorized supplementation) and none occurred in five ERC subjects (failure to dose). A post-hoc composite of three respiratory symptoms (trouble breathing, chest congestion and dry or hacking cough) resolved 3.0 days faster when 25D was elevated at Days 7 and 14 (p<0.05); chest congestion resolved 4.0 days faster with 25D increases of ≥25 ng/mL (p<0.05). Safety concerns including hypercalcemia were absent with ERC treatment.

Conclusions and Relevance ERC was effective in increasing serum 25D in outpatients with COVID-19, which may have accelerated resolution of respiratory symptoms suggesting mitigation of COVID-19 pneumonia risk, findings which warrant further study.

Competing Interest Statement

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: funding support was received from OPKO Health, Inc. (OPKO); Drs. Bishop, Ashfaq, Strugnell and Choe are employed by OPKO and have received stock options; Drs. Melnick and Kalantar-Zadeh are OPKO consultants; Dr. Ng is an employee of WuXi Clinical Trials engaged as a contractor for OPKO; Drs. Vazquez and Fialkow are paid OPKO clinical investigators; no other relationships or activities that could appear to have influenced the submitted work.

Clinical Trial

NCT04551911

Funding Statement

This study was funded by OPKO Health Inc.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Advarra (Columbia, MD), a central Institutional Review Board, gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Trial Registration: ClinicalTrials.gov identifier NCT04551911

Data Availability

All top-line data produced in the present study are contained in the manuscript. Additional analyses are ongoing as further laboratory data become available.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted February 05, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Results From the REsCue Trial: A Randomized Controlled Trial with Extended-Release Calcifediol in Symptomatic Outpatients with COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Results From the REsCue Trial: A Randomized Controlled Trial with Extended-Release Calcifediol in Symptomatic Outpatients with COVID-19
Charles W. Bishop, Akhtar Ashfaq, Joel Z. Melnick, Enrique Vazquez-Escarpanter, Jonathan A. Fialkow, Stephen A. Strugnell, John Choe, Kamyar Kalantar-Zadeh, Noah C. Federman, David Ng, John S. Adams
medRxiv 2022.01.31.22270036; doi: https://doi.org/10.1101/2022.01.31.22270036
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Results From the REsCue Trial: A Randomized Controlled Trial with Extended-Release Calcifediol in Symptomatic Outpatients with COVID-19
Charles W. Bishop, Akhtar Ashfaq, Joel Z. Melnick, Enrique Vazquez-Escarpanter, Jonathan A. Fialkow, Stephen A. Strugnell, John Choe, Kamyar Kalantar-Zadeh, Noah C. Federman, David Ng, John S. Adams
medRxiv 2022.01.31.22270036; doi: https://doi.org/10.1101/2022.01.31.22270036

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (559)
  • Anesthesia (135)
  • Cardiovascular Medicine (1774)
  • Dentistry and Oral Medicine (239)
  • Dermatology (173)
  • Emergency Medicine (316)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10826)
  • Forensic Medicine (8)
  • Gastroenterology (595)
  • Genetic and Genomic Medicine (2963)
  • Geriatric Medicine (289)
  • Health Economics (534)
  • Health Informatics (1935)
  • Health Policy (836)
  • Health Systems and Quality Improvement (746)
  • Hematology (294)
  • HIV/AIDS (634)
  • Infectious Diseases (except HIV/AIDS) (12530)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (89)
  • Nephrology (325)
  • Neurology (2815)
  • Nursing (152)
  • Nutrition (433)
  • Obstetrics and Gynecology (560)
  • Occupational and Environmental Health (600)
  • Oncology (1475)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (259)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (869)
  • Pharmacology and Therapeutics (368)
  • Primary Care Research (340)
  • Psychiatry and Clinical Psychology (2650)
  • Public and Global Health (5387)
  • Radiology and Imaging (1019)
  • Rehabilitation Medicine and Physical Therapy (598)
  • Respiratory Medicine (727)
  • Rheumatology (330)
  • Sexual and Reproductive Health (293)
  • Sports Medicine (279)
  • Surgery (328)
  • Toxicology (48)
  • Transplantation (150)
  • Urology (127)